13 Best ADR Stocks to Invest In

Page 2 of 12

11. Novartis AG (NYSE:NVS)

Number of Hedge Fund Holders: 33

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) has entered into a massive $1.7 billion partnership with British pharmaceutical firm Relation Therapeutics to develop treatments for allergic diseases, according to a report from Bloomberg which surfaced on December 9th. Through this deal, the firm will use Relation’s AI platform to develop new drugs by studying the genetics involved in diseases.

A day earlier, Novartis AG (NYSE:NVS)’s shares were upgraded to Overweight from Neutral by investment bank JPMorgan. As part of its coverage, the bank also raised the firm’s share price target to CHF125 from an earlier CHF95 as it based its optimism on the back of positive sentiment regarding the firm’s outlook for 2026.nNovartis AG (NYSE:NVS) has been busy with partnerships in 2025 as its deal with Relation isn’t the only one that it has inked. For instance, the firm bought Avidity Biosciences for a whopping $12 billion price tag in October. Through the deal, Novartis AG (NYSE:NVS) aims to boost its RNA drug development portfolio to cover rare ailments such as the Duchenne Muscular Atrophy. Apart from the Avidity deal, the Swiss pharma firm has also entered into agreements to buy Tourmaline Bio for $1.4 billion for its cardiovascular portfolio and Regulus Therapeutics for a $1.7 billion price tag to boost its renal portfolio.

Page 2 of 12